TY - JOUR
T1 - Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal
AU - El-Hachem, Nehme
AU - Eid, Edward
AU - Nemer, Georges
AU - Dbaibo, Ghassan
AU - Abbas, Ossama
AU - Rubeiz, Nelly
AU - Zeineldine, Salah
AU - Matar, Ghassan M.
AU - Bikorimana, Jean Pierre
AU - Shammaa, Riam
AU - Haibe-Kains, Benjamin
AU - Kurban, Mazen
AU - Rafei, Moutih
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/11/20
Y1 - 2020/11/20
N2 - The beginning of the 21st century has been marked by three distinct waves of zoonotic coronavirus outbreaks into the human population. The COVID-19 (coronavirus disease 2019) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emerged as a global threat endangering the livelihoods of millions worldwide. Currently, and despite collaborative efforts, diverse therapeutic strategies from ongoing clinical trials are still debated. To address the need for such an immediate call of action, we leveraged the largest dataset of drug-induced transcriptomic perturbations, public SARS-CoV-2 transcriptomic datasets, and expression profiles from normal lung transcriptomes. Most importantly, our unbiased systems biology approach prioritized more than 50 repurposable drug candidates (e.g., corticosteroids, Janus kinase and Bruton kinase inhibitors). Further clinical investigation of these FDA-approved candidates as monotherapy or in combination with an antiviral regimen (e.g., remdesivir) could lead to promising outcomes in patients with COVID-19.
AB - The beginning of the 21st century has been marked by three distinct waves of zoonotic coronavirus outbreaks into the human population. The COVID-19 (coronavirus disease 2019) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emerged as a global threat endangering the livelihoods of millions worldwide. Currently, and despite collaborative efforts, diverse therapeutic strategies from ongoing clinical trials are still debated. To address the need for such an immediate call of action, we leveraged the largest dataset of drug-induced transcriptomic perturbations, public SARS-CoV-2 transcriptomic datasets, and expression profiles from normal lung transcriptomes. Most importantly, our unbiased systems biology approach prioritized more than 50 repurposable drug candidates (e.g., corticosteroids, Janus kinase and Bruton kinase inhibitors). Further clinical investigation of these FDA-approved candidates as monotherapy or in combination with an antiviral regimen (e.g., remdesivir) could lead to promising outcomes in patients with COVID-19.
KW - Bioinformatics
KW - Systems Biology
KW - Virology
UR - http://www.scopus.com/inward/record.url?scp=85095425845&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2020.101697
DO - 10.1016/j.isci.2020.101697
M3 - Article
AN - SCOPUS:85095425845
SN - 2589-0042
VL - 23
JO - iScience
JF - iScience
IS - 11
M1 - 101697
ER -